| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We report the results of a prospective feasibility clinical trial for the use of an intradiscal injection of PRP-releasate in patients with degenerative disc disease (discogenic low back pain). First, no adverse effects were identified following treatment. The intradiscal injection of PRP-releasate has potential to reduce clinical LBP scores in 85% subjects.
The results of this study showed that gellan-sulfate, candidate for disc biomaterial, has potential to affect the matrix metabolism of intervertebral disc cells dependent on the ratio of sulfation. In vivo animal study showed that gellan-sulfate has high tissue compatibility, suggesting the possibility that gellan-sulfate would be effective biomaterial for intervertebral disc degeneration.
|
